Delivery Order SPE2DB20D1100-SPE2DB24FA5R0
Award Date
3/5/24
Potential Completion Date
3/6/24
Potential Value
$5.5K
Federal Agency
Defense Logistics Agency
Awardee
Amerisourcebergen Drug Corp
Ultimate Awardee
Not listed
NAICS Category
424210 - Drugs and Druggists' Sundries Merchant Wholesalers
PSC Category
6505 - Drugs And Biologicals
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, was awarded a $1,958.19 firm fixed price delivery order contract by the Defense Logistics Agency (DLA) to provide HEMABATE 250 MCG/ML AMPULML, a pharmaceutical product, with a completion date of March 5, 2024. This delivery order is issued under a larger indefinite delivery contract (IDC) held by Amerisourcebergen Drug Corp with DLA, with a potential value of $999,999,999.00 and a performance period through December...
The Defense Logistics Agency (DLA) awarded Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, a Firm Fixed Price delivery order contract (SPE2DB22D3011|SPE2DB24FQ0DX) valued at $5,522.91 to provide HEMABATE 250 MCG/ML AMPULML pharmaceutical products. The contract has a performance period through March 28, 2024 and was not set aside for any specific business type. Amerisourcebergen Drug Corp serves as a prime contractor to DLA Troop Support Medical, providing a wide range...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $4,239.50, is for the supply of HEMABATE 250 MCG/ML AMPULML, a pharmaceutical product. The contract has an ultimate completion date of January 22, 2025 and is a firm fixed-price contract. This contract does not have a set-aside designation, indicating it was competitively awarded....
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, for the delivery of HEMABATE 250 MCG/ML AMPULML. The award, valued at $6,555.04, is a firm fixed-price Delivery Order with a completion date of February 16, 2024. This contract does not have a set-aside designation, indicating it was competitively awarded. AmerisourceBergen holds a significant Indefinite Delivery...
This federal contract award was issued by the Defense Logistics Agency (DLA) Troop Support Medical to AmerisourceBergen Drug Corporation's Corporate Office division. The contract, valued at $4,862.12, is for the delivery of HEMABATE 250 MCG/ML AMPULML, a pharmaceutical product. This is a Firm Fixed Price delivery order contract with an ultimate completion date of October 8, 2024. The contract was awarded on October 7, 2024 and does not have a set-aside designation. AmerisourceBergen, a major...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the delivery of Hemabate 250 mcg/mL ampules. The contract has a ceiling value of $1,811.65 and a completion date of September 13, 2023. It is a firm-fixed-price delivery order contract, and there is no set-aside designation. AmerisourceBergen Drug Corp is a subsidiary of Cencora, Inc., the parent company, which holds a significant Indefinite...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the supply of HEMABATE 250 MCG/ML AMPULML, a pharmaceutical product, with a ceiling value of $2,714.70 and a period of performance through February 18, 2025. The contract is an Indefinite Delivery Contract (IDC) valued at $999,999,999 that serves as a primary vehicle for AmerisourceBergen to...
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $14,586.36 firm fixed-price delivery order is for the supply of HEMABATE 250 MCG/ML AMPUL/ML, a pharmaceutical product, with an ultimate completion date of October 23, 2024. The contract is not designated with a set-aside requirement, indicating open competition. Amerisourcebergen holds a significant $999,999,999...
This federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp is for the delivery of HEMABATE 250 MCG/ML AMPULML, a pharmaceutical product, with a ceiling value of $23,749.20. The contract is a Firm Fixed Price Delivery Order with a period of performance through November 29, 2023. AmerisourceBergen, a major pharmaceutical distributor, holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical division to provide a comprehensive...
This federal contract award is for the delivery of HEMABATE 250 MCG/ML AMPUL/ML, a pharmaceutical product, to the Defense Logistics Agency (DLA). The $20,848.30 firm fixed-price delivery order was issued to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc., on September 24, 2022 with a completion date of September 26, 2022. Amerisourcebergen is a major pharmaceutical distributor that holds significant Indefinite Delivery Contracts (IDCs) with the DLA Troop Support Medical and the...